International Review of Ophthalmology ›› 2021, Vol. 45 ›› Issue (5): 380-385.doi: 10.3760/cma.j.issn.1673-5803.2021.05.003

Previous Articles     Next Articles

Progress of topical pharmacotherapy for ocular surface squamous neoplasia

i Hanling, Zhao Zhiyuan, Zhang Hui   

  1. Department of Ophthalmology, the Fist Affiliated Hospital of Kunming Medical University, Kunming 650000, China
  • Received:2021-02-01 Online:2021-10-22 Published:2021-10-25
  • Contact: Zhang Hui, Email: huizh99@yahoo.com
  • Supported by:
    National Natural Science Foundation of China (81560159); 2020 Postgraduate Innovation Fund Project of Kunming Medical University (2020S134)　　

Abstract: Ocular surface squamous neoplasia（OSSN） is the most common ocular surface tumor. Topical pharmacotherapy, a non-invasive and less surgical trauma, has become the first way in the treatment of OSSN. At present, in addition to the chemotherapeutic drugs (such as mitomycin C, 5-fluorouracil, interferon α2b, retinoic acid)with anti-metabolic, anti-tumor and immunomodulatory effects, other antiangiogenic therapy and etiological treatment (such as anti- vascular endothelial growth factor, cidofovir) have also been used in the clinical treatment of OSSN.  (Int Rev Ophthalmol, 2020, 45： 380-386)

Key words: ocular surface squamous neoplasia, topical pharmacotherapy, non-operative treatment